Original Article
Impaired Expression of the Thrombopoietin Receptor by Platelets from Patients with Polycythemia Vera
N Engl J Med 1998; 338:572-580February 26, 1998
- Abstract
Background
The cause of polycythemia vera, which originates from a multipotent hematopoietic progenitor cell, is unknown. Thrombopoietin is a hematopoietic growth factor that regulates the production of multipotent hematopoietic progenitor cells and platelets. To evaluate the possibility that an abnormality in thrombopoietin-mediated signal transduction might be involved in the pathogenesis of polycythemia vera, we examined thrombopoietin-induced tyrosine phosphorylation of proteins and the expression of the thrombopoietin receptor in platelets from patients with the disease.
Methods
Platelets were isolated from the blood of patients with polycythemia vera or other chronic myeloproliferative disorders and control subjects. The platelets were exposed to either thrombopoietin or thrombin and then lysed for analysis of tyrosine phosphorylation of platelet proteins and the expression of the proteins by means of immunoblotting. Expression of the thrombopoietin receptor (Mpl) by platelets and megakaryocytes was also assessed.
Results
Thrombopoietin-mediated tyrosine phosphorylation of proteins was impaired in platelets from 20 patients with polycythemia vera and 3 with idiopathic myelofibrosis, but not in 4 patients with essential thrombocytosis, 3 with chronic myelogenous leukemia, 6 with secondary erythrocytosis, 2 with iron-deficiency anemia, 4 with hemochromatosis, or 5 normal subjects. Thrombin-mediated tyrosine phosphorylation of proteins was intact in platelets from patients with polycythemia vera, and the tyrosine kinases and substrates involved in the process were present in normal amounts. However, expression of the platelet thrombopoietin receptor Mpl was markedly reduced or absent in 34 of 34 patients with polycythemia vera and in 13 of 14 patients with idiopathic myelofibrosis. Impaired thrombopoietin-induced tyrosine phosphorylation of proteins in patients with these two diseases was uniformly associated with markedly reduced expression of Mpl or the lack of its expression. In patients with polycythemia vera, reduced expression of Mpl by platelets was associated with reduced expression of Mpl by megakaryocytes.
Conclusions
Reduced expression of the thrombopoietin receptor Mpl is characteristic of polycythemia vera and idiopathic myelofibrosis. The abnormality appears to distinguish polycythemia vera from other forms of erythrocytosis.
Media in This Article
Figure 1
Tyrosine Phosphorylation of Proteins in Platelet Lysates from Normal Subjects and Patients with Polycythemia Vera (PV).Figure 2
Tyrosine Phosphorylation of JAK2 (Panel A) and Its Substrate STAT5 (Panel B) in Platelet Lysates from Normal Subjects and Patients with Polycythemia Vera (PV).Article Activity
- Article
Polycythemia vera, idiopathic myelofibrosis, chronic myelogenous leukemia, and essential thrombocythemia are classified as chronic myeloproliferative disorders because they arise through the clonal expansion of a multipotent hematopoietic progenitor cell, with subsequent overproduction of one or more of the formed elements of the blood.1-4 With the exception of chronic myelogenous leukemia, these disorders lack a clonal marker, their pathogenesis is unknown, and the diagnosis depends on clinical criteria.
Polycythemia vera is characterized by increased numbers of erythrocytes, granulocytes, and platelets. Since erythrocytosis is the most prominent manifestation and the defining clinical criterion of polycythemia vera, most studies of the disease have focused on erythropoiesis. The erythroid progenitor cells in patients with polycythemia vera proliferate and differentiate in vitro in the absence of added erythropoietin,5,6 and they are hypersensitive to other growth factors under certain conditions.7-10 However, although erythropoietin-independent formation of erythroid colonies in vitro is characteristic of polycythemia vera, it is not specific for the disease7,11 and does not define the limits of the affected clone, since not all erythroid progenitors in polycythemia vera are independent of erythropoietin.6
Given these attributes of erythroid progenitor cells in polycythemia vera, there has been substantial interest in the function of growth factor receptors in this disease. However, the expression of the erythropoietin receptor and its ability to bind to erythropoietin are normal in polycythemia vera,12 and abnormalities of the erythropoietin receptor gene have not been identified.11,13,14 Mutations of this gene have been found in families with inherited erythrocytosis,15,16 but affected family members do not have disorders of thrombopoiesis and granulopoiesis.
In contrast to these studies of the erythropoietin receptor, recent studies suggest that an alteration of thrombopoietin-mediated signal transduction might be implicated in polycythemia vera. The best-characterized effect of thrombopoietin appears to be on the proliferation and differentiation of megakaryocyte precursors,17 but thrombopoietin also acts directly on primitive hematopoietic stem cells in vitro,18 and mice with a deficiency of thrombopoietin or its receptor (designated Mpl) have reduced numbers of both multilineage and committed hematopoietic progenitor cells.19 Overexpression of thrombopoietin in mice leads to extramedullary hematopoiesis and myelofibrosis,20 whereas ectopic expression of Mpl produces a fatal erythroblastosis.21 Moreover, the retrovirus MPLV, which carries a truncated Mpl gene, induces erythrocytosis, thrombocytosis, granulocytosis, and splenomegaly in mice,22 and hematopoietic progenitor cells infected with MPLV in vitro are not dependent on growth factors.23
For these reasons, we hypothesized that an abnormality of the thrombopoietin–Mpl signal-transduction pathway might be present in patients with polycythemia vera. To evaluate this possibility, we investigated thrombopoietin-induced signal transduction and the thrombopoietin receptor in patients with polycythemia vera. Since platelets express Mpl24 and because the blood cells in polycythemia vera are derived from an abnormal clone,1 we studied thrombopoietin-induced signal transduction in platelets. We observed that thrombopoietin-induced tyrosine phosphorylation of proteins in vitro was impaired in platelets from patients with polycythemia vera, as compared with normal platelets, and that this signaling defect was associated with diminished expression of the thrombopoietin receptor in platelets and megakaryocytes. In contrast to previously described abnormalities of platelets in patients with polycythemia vera, which can vary from patient to patient,25-27 Mpl deficiency was observed in the platelets from all 34 patients with polycythemia vera whom we studied. Furthermore, this abnormality distinguished platelets from patients with polycythemia vera from those from patients with benign (secondary) erythrocytosis.
Methods
Subjects
We studied 64 patients with chronic myeloproliferative disorders: 34 with polycythemia vera, 14 with idiopathic myelofibrosis, 9 with essential thrombocytosis, and 7 with chronic myelogenous leukemia. The study protocol was approved by our joint committee on clinical investigation, and informed consent was obtained from each patient. The diagnosis of polycythemia vera was based on the criteria of the Polycythemia Vera Study Group 28 and included an elevated red-cell mass. The diagnosis of the other chronic myeloproliferative disorders was based on standard clinical criteria.29 Control subjects included 14 patients with erythrocytosis (due in 2 patients to renal transplantation, to congenital heart disease in 1 patient, to a hemoglobin variant in 1 patient, and to unknown causes in 10 patients), 8 patients with hemochromatosis who were undergoing periodic therapeutic phlebotomy, 2 patients with uncomplicated iron deficiency, and 10 normal subjects (Table 1Table 1
Clinical and Laboratory Characteristics of the Study Subjects.).Tyrosine Phosphorylation of Platelet Proteins
Venous blood collected in 3.8 percent sodium citrate was centrifuged at 160×g for 10 minutes to obtain platelet-rich plasma. The platelet-rich plasma was spun at 750×g for 12 minutes, and the platelet pellet was washed three times with phosphate-buffered saline containing 0.5 percent bovine serum albumin and 0.6 percent sodium citrate (wash buffer). The platelets were resuspended in the wash buffer and enumerated in an electronic particle counter, and the volume of buffer was adjusted to yield a platelet concentration of 10 9 cells per milliliter. Platelets were exposed to thrombin or thrombopoietin at selected concentrations for the indicated times at room temperature and then lysed in 20 mM TRIS buffer (pH 7.5) containing 1 percent Nonidet P 40, 137 mM sodium chloride, 10 percent glycerol, 1 mM EDTA, 50 mM sodium fluoride, 5 mM magnesium chloride, 2 mM sodium vanadate, 1 mM phenylmethylsulfonyl fluoride, 2 μg of aprotinin per milliliter, 2 μg of leupeptin per milliliter, and 1 μg of pepstatin per milliliter (lysis buffer). The protein concentration of the platelet lysates was quantitated by the bicinchoninic acid technique.30
Immunoblotting and Immunoprecipitation of Platelet Lysates
Equal aliquots of platelet lysate protein were subjected to sodium dodecylsulfate–7.5 percent polyacrylamide-gel electrophoresis (SDS-PAGE) and then transferred to a nitrocellulose membrane at 20 V for 16 hours. The membrane was blocked with a solution of 10 mmol of TRIS per liter, 150 mmol of sodium chloride per liter (pH 7.6), and 1 percent Tween 20 (TBST) and 5 percent bovine serum albumin at room temperature for one hour, washed three times with TBST, and then incubated in TBST with 1 μg of primary antibody per milliliter for one hour. The membrane was washed three times, incubated for one hour with the appropriate horseradish peroxidase–linked secondary antibody diluted 1:10,000 in TBST, and then washed three times. Detection by enhanced chemiluminescence was performed according to the manufacturer's specifications (Amersham, Arlington Heights, Ill.). Membranes were reprobed with different antibodies after stripping in 62.5 mmol of TRIS per liter (pH 6.7) with 2 percent SDS and 100 mmol of mercaptoethanol per liter at 70°C for 30 minutes. For immunoprecipitation, antibody was added to the platelet lysate (200 μg of lysate diluted to 1 μg per microliter in lysis buffer) at a concentration of 1 μg per 0.1 ml and incubated at 4°C for two hours. Protein A Sepharose (Pharmacia Biotech, Uppsala, Sweden), 0.1 ml of a 50 percent slurry in lysis buffer, was added to the lysate and incubated for an additional hour at 4°C with rocking. The sample was then washed four times with 10 mM TRIS buffer (pH 7.4) containing 1 percent Triton X-100, 150 mM sodium chloride, 1 mM ethyleneglycol-bis-(β-aminoethylether)-N,N,N',N'-tetraacetic acid, 2 mM sodium vanadate, and 1 mM phenylmethylsulfonyl fluoride; resuspended in SDS-PAGE sample buffer; boiled for five minutes; subjected to SDS-PAGE; and transferred to a nitrocellulose membrane for immunoblotting as described above.
Densitometric Analysis
Autoradiographs of immunoblots were scanned with a Hewlett–Packard ScanJet IIc (Hewlett–Packard, Palo Alto, Calif.) and densitometry was performed with NIH Image software (version 2.3). Absorbance of the 85-kd band (Mpl) was quantified as the area under the peak for the band and expressed in arbitrary absorbance units. Pilot experiments identified the amount of platelet lysate protein (35 μg) that produced a linear response. Protein loading was controlled by reprobing the membrane with glycoprotein IIIa antiserum to confirm that similar amounts of platelet lysate were present in each sample. The expression of Mpl was determined by dividing the values for the patients by the average values for the control subjects on the same immunoblot. The variation in responses among the control subjects on a given immunoblot never exceeded 15 percent.
Immunohistochemical Analysis of Bone Marrow Biopsies
Sequential bone marrow–biopsy sections from patients with polycythemia vera or control subjects were either exposed to the affinity-purified rabbit Mpl antiserum at a dilution of 1:300 or incubated first with protease XXVII (Sigma) for 20 minutes and then with goat antihuman von Willebrand antiserum (Dako, Carpinteria, Calif.) at a dilution of 1:100, followed by exposure to the appropriate peroxidase-labeled secondary antibody and substrate.
Plasma Thrombopoietin Assay
Thrombopoietin was measured in EDTA-treated plasma samples from patients and controls with an enzyme-linked immunoassay (Amgen, Thousand Oaks, Calif.).31 The mean value in normal subjects was 133 pg per milliliter (range, 55 to 377). The interassay variation was 15 percent, and the intraassay variation was 10 percent.
Platelet Flow Cytometry
Platelet-rich plasma prepared as described above was incubated with nonspecific rabbit IgG or Mpl antiserum for 30 minutes at 4°C, washed once, exposed to a goat antirabbit fluorescein conjugate F(ab')2 fragment (Boehringer Mannheim, Indianapolis) for 30 minutes at 4°C, and washed again with wash buffer. Then 10,000 labeled platelets were analyzed with a FACScan flow cytometer (Becton Dickinson, San Jose, Calif.) according to the manufacturer's specifications.
Reagents and Antibodies
The antiphosphotyrosine antibody PY20 and STAT5 antiserum were purchased from Santa Cruz Biotechnology (Santa Cruz, Calif.). The JAK2 antiserum was purchased from Upstate Biotechnology (Lake Placid, N.Y.). Affinity-purified, polyclonal rabbit IgG antibodies to the soluble extracellular domain of human Mpl was a gift from Kirin Brewery (Maebashi, Gunma, Japan). Platelet glycoprotein IIIa antiserum was kindly supplied by Dr. Paul Bray (Hematology Division, Johns Hopkins University School of Medicine, Baltimore). Full-length thrombopoietin was purchased from R & D Systems (Minneapolis). Bovine thrombin was purchased from Armour Pharmaceutical Company (Collegeville, Pa.).
Statistical Analysis
Plasma thrombopoietin levels are not normally distributed. Therefore, the significance of the differences between group means of the thrombopoietin assay was assessed by the Kruskal–Wallis analysis of variance in ranks and Dunn's method for pairwise multiple comparisons.
Results
Tyrosine Phosphorylation of Platelet Proteins
Incubation of normal platelets with thrombopoietin or thrombin induced tyrosine phosphorylation of numerous proteins in a dose-dependent and time-dependent manner. After the exposure of platelets from five normal subjects to a saturating concentration of thrombopoietin (100 ng per milliliter), proteins with apparent molecular masses of 125, 95, and 85 kd underwent tyrosine phosphorylation (Figure 1Figure 1
Tyrosine Phosphorylation of Proteins in Platelet Lysates from Normal Subjects and Patients with Polycythemia Vera (PV).). By contrast, incubation of platelets from patients with polycythemia vera in a similar concentration of thrombopoietin failed to induce significant tyrosine phosphorylation of these proteins. This phenomenon, which was found in 20 of 20 patients with polycythemia vera, and in 3 of 3 patients with idiopathic myelofibrosis, was not caused by a global impairment of tyrosine phosphorylation, since thrombin induced similar patterns of tyrosine phosphorylation in platelets from both normal subjects and patients with polycythemia vera. Neither increasing the concentration of thrombopoietin (up to 1000 ng per milliliter) nor increasing the duration of exposure to thrombopoietin (up to 30 minutes) induced substantial tyrosine phosphorylation in platelets from patients with polycythemia vera (data not shown).The thrombopoietin receptor Mpl lacks a kinase domain.32 Instead, thrombopoietin-induced signal transduction by Mpl involves activation of JAK2 and Tyk2, which are members of the Janus family of tyrosine kinases.33-37 We examined tyrosine phosphorylation of JAK2 after exposure of platelets from normal subjects and patients with polycythemia vera to thrombopoietin. As shown in Figure 2AFigure 2
Tyrosine Phosphorylation of JAK2 (Panel A) and Its Substrate STAT5 (Panel B) in Platelet Lysates from Normal Subjects and Patients with Polycythemia Vera (PV)., thrombopoietin-induced tyrosine phosphorylation of JAK2 was impaired in platelets from patients with polycythemia vera, even though immunoblotting showed that the amount of JAK2 protein present in these platelets was similar to that in the normal platelets. Tyrosine phosphorylation of Tyk2 was also impaired in platelets from patients with polycythemia vera after exposure to thrombopoietin despite the presence of equivalent quantities of Tyk2 protein in the two types of platelets (data not shown).To determine whether impaired tyrosine phosphorylation of JAK2 also impaired phosphorylation of its substrate proteins,38 we examined the electrophoretic mobility of one of these substrates, STAT5, in platelets from normal subjects and patients with polycythemia vera after exposure to thrombopoietin. As shown in Figure 2B, the addition of thrombopoietin to normal platelets significantly reduced the electrophoretic mobility of STAT5, an effect that correlated with an increase in its tyrosine phosphorylation (data not shown). In platelets from patients with polycythemia vera, however, the mobility of STAT5 was unchanged after incubation with thrombopoietin, and it did not undergo tyrosine phosphorylation. The absence of a mobility shift is further evidence of impaired thrombopoietin-mediated signal transduction in patients with polycythemia vera. These data indicate that the diminished tyrosine phosphorylation of STAT5 was due to an upstream defect in JAK2, Mpl, or other components of the thrombopoietin signaling pathway.
Expression of Mpl by Platelets
The abnormalities that we found in tyrosine phosphorylation of platelet proteins in patients with polycythemia vera could reflect an abnormality in the Janus kinases or Mpl. Since the amount and electrophoretic mobility of JAK2 (and Tyk2) appeared to be normal in these platelets, we examined the expression of platelet Mpl using immunoblotting. As shown in Figure 3AFigure 3
Loss of the Thrombopoietin Receptor in Platelets from Patients with Polycythemia Vera (PV). and Table 2Table 2
Densitometric Analysis of the Expression of Mpl by Platelets from 10 Patients with Polycythemia Vera and 2 Patients with Idiopathic Myelofibrosis., for equal quantities of platelet lysate protein, expression of the thrombopoietin receptor was markedly reduced in platelets from patients with polycythemia vera as compared with platelets from normal subjects. Flow-cytometric analysis of fresh, unfixed platelets yielded a concordant finding, indicating that the result with immunoblotting was not due to manipulation of the platelets (Figure 3B). To ensure that the impaired expression of Mpl by platelets from patients with polycythemia vera was not a consequence of proteolysis during the isolation of platelets or of down-regulation by thrombopoietin or by as yet undefined agents in the plasma of the patients, we examined the expression of Mpl in lysates prepared from a mixture of equal quantities of platelets from normal subjects and patients with polycythemia vera, after incubation of normal platelets in plasma from patients with polycythemia vera, or after prolonged exposure of normal platelets to a saturating concentration of thrombopoietin. In no instance was the expression of Mpl impaired in the normal platelets (data not shown).Reduced Expression of Platelet Mpl as a Marker for Polycythemia Vera and Idiopathic Myelofibrosis
To assess the specificity of these observations, we examined the expression of Mpl by platelets from 34 patients with polycythemia vera, 14 patients with idiopathic myelofibrosis, 9 patients with essential thrombocytosis, 7 patients with chronic myelogenous leukemia, 14 patients with secondary or undefined erythrocytosis, 8 patients with hemochromatosis who were undergoing periodic therapeutic phlebotomy, 2 patients with uncomplicated iron deficiency, and 10 normal subjects. The expression of Mpl was decreased in platelets from all 34 patients with polycythemia vera, whereas the expression of Mpl was not diminished in platelets from the patients with essential thrombocytosis, chronic myelogenous leukemia, erythrocytosis, hemochromatosis, or iron deficiency or in the normal subjects. There was no correlation between decreased expression of Mpl in the patients with polycythemia vera and the platelet count, hemoglobin level, leukocyte count, duration of disease, presence or size of the spleen, the presence of iron deficiency, aspirin use, or concurrent use of hydroxyurea or interferon alfa therapy (data not shown). Interestingly, platelet expression of Mpl was also decreased in 13 of the 14 patients with idiopathic myelofibrosis. The concordance for decreased thrombopoietin-induced tyrosine phosphorylation of proteins and decreased expression of Mpl was 100 percent in the 18 patients (16 with polycythemia vera and 2 with idiopathic myelofibrosis) with sufficient platelet samples for both assays.
Expression of Mpl by Megakaryocytes
To determine whether expression of the thrombopoietin receptor was reduced in megakaryocytes from patients with polycythemia vera, bone marrow–biopsy specimens were examined by immunohistochemical staining with affinity-purified rabbit antibodies against Mpl. As shown in Figure 4AFigure 4
Immunohistochemical Staining of Sequential Bone Marrow–Biopsy Sections with von Willebrand Factor Antiserum (Panels A and C) or Mpl Antiserum (Panels B and D) in a Patient with Essential Thrombocytosis (Upper Panels, ×64) and a Patient with Polycythemia Vera (Lower Panels, ×100)., Figure 4B, Figure 4C, and Figure 4D, as compared with results in a control patient with essential thrombocytosis, in a patient with polycythemia vera the expression of Mpl was markedly reduced in 13 of the 14 megakaryocytes identified in a section stained for von Willebrand factor. Similar results were obtained in megakaryocytes from nine other patients with polycythemia vera and five patients with idiopathic myelofibrosis.Plasma Thrombopoietin Levels in Patients with Polycythemia Vera
Previous studies have established that there is an inverse correlation between megakaryocyte and platelet mass and plasma thrombopoietin levels, which presumably results from the down-regulation of thrombopoietin due to receptor–ligand interactions.39,40 We therefore measured plasma thrombopoietin levels in patients with polycythemia vera and idiopathic myelofibrosis and normal subjects. We found that the mean plasma thrombopoietin concentration was significantly higher (P<0.05) in patients with polycythemia vera (407 pg per milliliter) and patients with idiopathic myelofibrosis (292 pg per milliliter) than in normal subjects (133 pg per milliliter). There was no correlation, however, between the platelet count and the plasma thrombopoietin level in the patients with polycythemia vera.
Discussion
The chronic myeloproliferative disorders polycythemia vera, idiopathic myelofibrosis, and essential thrombocytosis originate in a multipotent hematopoietic progenitor cell, and all are characterized by an increase in one or more types of blood cells. However, clonal markers have not been identified for these disorders, and their pathogenesis is not understood. Furthermore, polycythemia vera may present with an isolated leukocytosis, thrombocytosis, or even myelofibrosis and myeloid metaplasia and may eventually evolve into idiopathic myelofibrosis, making it difficult to distinguish among the three disorders. This problem is not trivial, since the natural history, treatment, and prognosis of polycythemia vera, idiopathic myelofibrosis, and essential thrombocytosis differ.29
Recent experimental data suggest that an abnormality of the thrombopoietin-mediated signal-transduction pathway might be involved in polycythemia vera.17-21 Assessment of the expression of Mpl, the thrombopoietin receptor, by platelets provided a way to test this hypothesis. Binding of thrombopoietin to Mpl causes oligomerization of Mpl and activation of members of the Janus family of tyrosine kinases, in particular JAK2 and Tyk2.34-37 Activation of these kinases is associated with tyrosine phosphorylation of a number of proteins, including members of the STAT family (in platelets, STAT3 and STAT5 specifically) and Shc.35-38 We found that exposure of platelets from patients with polycythemia vera to thrombopoietin failed to activate JAK2 or Tyk2, and as a consequence STAT5 did not undergo tyrosine phosphorylation, even though the two kinases and the STAT5 substrate were expressed normally and thrombin-induced tyrosine phosphorylation of platelet proteins was intact. In contrast to findings in patients with chronic myelogenous leukemia, in whom growth factor–independent tyrosine phosphorylation of platelet proteins occurs as a consequence of the constitutively active kinase Bcr-Abl,41 we found no constitutive tyrosine phosphorylation of platelet proteins in patients with polycythemia vera.
The basis of the abnormality in thrombopoietin-mediated signal transduction in polycythemia vera appears to be diminished expression of the receptor for thrombopoietin in platelets. The findings of diminished expression of platelet prostaglandin D2 receptors in some patients with chronic myeloproliferative disorders42 and α-adrenergic receptors in the platelets of some patients with essential thrombocytosis43 parallel our observations, but the remarkable consistency of the reduction in the expression of Mpl in platelets and megakaryocytes from patients with polycythemia vera is novel. It is of interest that platelets from 13 of 14 patients with idiopathic myelofibrosis expressed a similar defect in the expression of Mpl. This finding suggests a close biologic relation between polycythemia vera and idiopathic myelofibrosis, which are known to be related clinically. The reduced expression of Mpl was specific for polycythemia vera (as defined by the currently accepted clinical criteria)28 and was not a consequence of iron deficiency, splenomegaly, prior therapy (including periodic phlebotomy), duration of disease, or a hyperactive bone marrow. Nor was it found among patients with erythrocytosis unrelated to polycythemia vera.
The diminished expression of Mpl by platelets and megakaryocytes from patients with polycythemia vera was unexpected in a disease characterized by an excess of hematopoietic cells and hypersensitivity to growth factors. We found no evidence that the lack of Mpl was due to accelerated degradation of the receptor or its down-regulation by thrombopoietin. Overexpression of either thrombopoietin or Mpl in murine models produces many of the clinical features of polycythemia vera and idiopathic myelofibrosis,20,21 whereas mice with disabled Mpl genes have thrombocytopenia and reduced numbers of hematopoietic progenitor cells.19 However, it may be misleading to draw parallels between polycythemia vera and genetically manipulated animal models. First, since polycythemia vera is an acquired disorder and presumably heterozygous, it may not be appropriate to compare it with a homozygous knockout model in mice. Second, loss of expression of a growth factor receptor may reflect the independence of the clonal progenitor cell in polycythemia vera from growth factors that are normally essential. Third, reduced expression or function of these receptors may produce unanticipated effects in cells that express a variety of other growth factor receptors. For example, inherited or experimentally induced mutations of the erythropoietin-receptor gene that cause carboxy-terminal truncations are associated with erythrocytosis due to hypersensitivity to insulin-like growth factor I but not to erythropoietin.44 There is, moreover, the intriguing in vitro observation that erythroid progenitor cells in polycythemia vera have heightened sensitivity to a variety of hematopoietic growth factors but principally to insulin-like growth factor I.7
We cannot state that the loss of the thrombopoietin receptor is the cause of polycythemia vera, but the uniformity of this abnormality in platelets and megakaryocytes from affected patients suggests that it is intimately connected with the disease process. Whether reduced expression of Mpl represents a late consequence of the abnormality causing polycythemia vera or an obligatory early event, our finding provides a new avenue for investigation of the pathogenesis of this disease.
Supported by a grant from the National Institutes of Health (R01-H158589, to Dr. Spivak) and a Stetler Research Fellowship (to Dr. Moliterno).
We are indebted to Mrs. Evelyn Connor, Mrs. Mary Ann Isaacs, Ms. Karen Siebel, and Mr. Albert Sun for expert technical assistance.
Source Information
From the Hematology Division, Department of Medicine, Johns Hopkins University School of Medicine, Traylor 924, 720 Rutland Ave., Baltimore, MD 21205, where reprint requests should be addressed to Dr. Spivak.
- References
References
1
Adamson JW ,Fialkow PJ ,Murphy S ,Prchal JF ,Steinmann L . Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 1976;295:913-916
Full Text | Web of Science | Medline2
Jacobson RJ ,Salo A ,Fialkow PJ . Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978;51:189-194
Web of Science | Medline3
Fialkow PJ ,Jacobson RJ ,Singer JW ,Sacher RA ,McGuffin RW ,Neefe JR . Philadelphia chromosome (Ph1)-negative chronic myelogenous leukemia (CML): a clonal disease with origin in a multipotent stem cell. Blood 1980;56:70-73
Web of Science | Medline4
Fialkow PJ ,Faguet GB ,Jacobson RJ ,Vaidya K ,Murphy S . Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981;58:916-919
Web of Science | Medline5
Prchal JF ,Axelrad AA . Bone-marrow responses in polycythemia vera. N Engl J Med 1974;290:1382-1382
Web of Science | Medline6
Cashman J ,Henkelman D ,Humphries K ,Eaves C ,Eaves A . Individual BFU-E in polycythemia vera produce both erythropoietin dependent and independent progeny. Blood 1983;61:876-884
Web of Science | Medline7
Correa PN ,Eskinazi D ,Axelrad AA . Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium. Blood 1994;83:99-112
Web of Science | Medline8
de Wolf JT ,Beentjes JA ,Esselink MT , et al. In polycythemia vera human interleukin 3 and granulocyte-macrophage colony-stimulating factor enhance erythroid colony growth in the absence of erythropoietin. Exp Hematol 1989;17:981-983
Web of Science | Medline9
Dai CH ,Krantz SB ,Dessypris EN ,Means RT Jr ,Horn ST ,Gilbert HS . Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood 1992;80:891-899
Web of Science | Medline10
Dai CH ,Krantz SB ,Green WF ,Gilbert HS . Polycythemia vera. III. Burst-forming units-erythroid (BFU-E) response to stem cell factor and c-kit receptor expression. Br J Haematol 1994;86:12-21
CrossRef | Web of Science | Medline11
Emanuel PD ,Eaves CJ ,Broudy VC , et al. Familial and congenital polycythemia in three unrelated families. Blood 1992;79:3019-3030
Web of Science | Medline12
Means RT Jr ,Krantz SB ,Sawyer ST ,Gilbert HS . Erythropoietin receptors in polycythemia vera. J Clin Invest 1989;84:1340-1344
CrossRef | Web of Science | Medline13
Le Couedic JP ,Mitjavila MT ,Villeval JL , et al. Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies. Blood 1996;87:1502-1511
Web of Science | Medline14
Hess G ,Rose P ,Gamm H ,Papadileris S ,Huber C ,Seliger B . Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera. Br J Haematol 1994;88:794-802
CrossRef | Web of Science | Medline15
de la Chapelle A ,Traskelin AL ,Juvonen E . Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci U S A 1993;90:4495-4499
CrossRef | Web of Science | Medline16
Sokol L ,Luhovy M ,Guan Y ,Prchal JF ,Semenza GL ,Prchal JT . Primary familial polycythemia: a frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin. Blood 1995;86:15-22
Web of Science | Medline17
Kaushansky K . Thrombopoietin: the primary regulator of platelet production. Blood 1995;86:419-431
Web of Science | Medline18
Ku H ,Yonemura Y ,Kaushansky K ,Ogawa M . Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Blood 1996;87:4544-4551
Web of Science | Medline19
Carver-Moore K ,Broxmeyer HE ,Luoh SM , et al. Low levels of erythroid and myeloid progenitors in thrombopoietin- and c-mpl-deficient mice. Blood 1996;88:803-808
Web of Science | Medline20
Yan XQ ,Lacey D ,Fletcher F , et al. Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood 1995;86:4025-4033
Web of Science | Medline21
Cocault L ,Bouscary D ,Le Bousse Kerdiles C , et al. Ectopic expression of murine TPO receptor (c-mpl) in mice is pathogenic and induces erythroblastic proliferation. Blood 1996;88:1656-1665
Web of Science | Medline22
Wendling F ,Varlet P ,Charon M ,Tambourin P . MPLV: a retrovirus complex inducing an acute myeloproliferative leukemic disorder in adult mice. Virology 1986;149:242-246
CrossRef | Web of Science | Medline23
Souyri M ,Vigon I ,Penciolelli JF ,Heard JM ,Tambourin P ,Wendling F . A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 1990;63:1137-1147
CrossRef | Web of Science | Medline24
Debili N ,Wendling F ,Cosman D , et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 1995;85:391-401
Web of Science | Medline25
Berger S ,Aledort LM ,Gilbert HS ,Hanson JP ,Wasserman LR . Abnormalities of platelet function in patients with polycythemia vera. Cancer Res 1973;33:2683-2687
Web of Science | Medline26
Raman BK ,Van Slyck EJ ,Riddle J ,Sawdyk MA ,Abraham JP ,Saeed SM . Platelet function and structure in myeloproliferative disease, myelodysplastic syndrome, and secondary thrombocytosis. Am J Clin Pathol 1989;91:647-655
Web of Science | Medline27
Schafer AI . Deficiency of platelet lipoxygenase activity in myeloproliferative disorders. N Engl J Med 1982;306:381-386
Full Text | Web of Science | Medline28
Berk PD ,Goldberg JD ,Donovan PB ,Fruchtman SM ,Berlin NI ,Wasserman LR . Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986;23:132-143
Web of Science | Medline29
Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, eds. Hematology: basic principles and practice. 2nd ed. New York: Churchill Livingstone, 1995.
30
Smith PK ,Krohn RI ,Hermanson GT , et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985;150:76-85
CrossRef | Web of Science | Medline31
Marsh JCW ,Gibson FM ,Prue RL , et al. Serum thrombopoietin levels in patients with aplastic anaemia. Br J Haematol 1996;95:605-610
CrossRef | Web of Science | Medline32
Taniguchi T . Cytokine signaling through nonreceptor protein tyrosine kinases. Science 1995;268:251-255
CrossRef | Web of Science | Medline33
Vignon I ,Mornon JP ,Cocault L , et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci U S A 1992;89:5640-5644
CrossRef | Web of Science | Medline34
Tortolani PJ ,Johnston JA ,Bacon CM , et al. Thrombopoietin induces tyrosine phosphorylation and activation of the Janus kinase, JAK2. Blood 1995;85:3444-3451
Web of Science | Medline35
Drachman JG ,Griffin JD ,Kaushansky K . The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. J Biol Chem 1995;270:4979-4982
CrossRef | Web of Science | Medline36
Ezumi Y ,Takayama H ,Okuma M . Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett 1995;374:48-52
CrossRef | Web of Science | Medline37
Miyakawa Y ,Oda A ,Druker BJ , et al. Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets. Blood 1995;86:23-27
Web of Science | Medline38
Miyakawa Y ,Oda A ,Druker BJ , et al. Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Blood 1996;87:439-446
Web of Science | Medline39
Kuter DJ ,Rosenberg RD . The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995;85:2720-2730
Web of Science | Medline40
Emmons RVB ,Reid DM ,Cohen RL , et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996;87:4068-4071
Web of Science | Medline41
Oda A ,Miyakawa Y ,Druker BJ , et al. Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin. Blood 1996;88:4304-4313
Web of Science | Medline42
Cooper B ,Ahern D . Characterization of the platelet prostaglandin D2 receptor: loss of prostaglandin D2 receptors in platelets of patients with myeloproliferative disorders. J Clin Invest 1979;64:586-590
CrossRef | Web of Science | Medline43
Kaywin P ,McDonough M ,Insel PA ,Shattil SJ . Platelet function in essential thrombocythemia: decreased epinephrine responsiveness associated with a deficiency of platelet α-adrenergic receptors. N Engl J Med 1978;299:505-509
Full Text | Web of Science | Medline44
Damen JE ,Krystal G . Early events in erythropoietin-induced signaling. Exp Hematol 1996;24:1455-1459
Web of Science | Medline
- Citing Articles (108)
Citing Articles
1
Huiyuan Li, Haifeng Zhao, Donghai Wang, Renchi Yang. (2011) microRNA regulation in megakaryocytopoiesis. British Journal of Haematology 155:3, 298-307
CrossRef2
Catherine L. Carmichael, Warren S. Alexander. (2011) Mouse models of diseases of megakaryocyte and platelet homeostasis. Mammalian Genome 22:7-8, 449-465
CrossRef3
Luciana Teofili, Luigi M. Larocca. (2011) Advances in understanding the pathogenesis of familial thrombocythaemia. British Journal of Haematology 152:6, 701-712
CrossRef4
Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes, Srdan Verstovsek. (2011) Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nature Reviews Drug Discovery 10:2, 127-140
CrossRef5
M. Girardot, C. Pecquet, S. Boukour, L. Knoops, A. Ferrant, W. Vainchenker, S. Giraudier, S. N. Constantinescu. (2010) miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. Blood 116:3, 437-445
CrossRef6
Stephen T Oh, Jason Gotlib. (2010) JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Review of Hematology 3:3, 323-337
CrossRef7
Ana C. Glembotsky, Laura Korin, Paola R. Lev, Carlos D. Chazarreta, Rosana F. Marta, Felisa C. Molinas, Paula G. Heller. (2010) Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPL W515L-positive platelets. European Journal of Haematology 84:5, 398-405
CrossRef8
François Delhommeau, Dorota Jeziorowska, Christophe Marzac, Nicole Casadevall. (2010) Molecular aspects of myeloproliferative neoplasms. International Journal of Hematology 91:2, 165-173
CrossRef9
M. L. Randi, A. M. Brunati, M. Scapin, M. Frasson, R. Deana, E. Magrin, F. Fabris, A. Donella-Deana. (2010) Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera. Blood 115:3, 667-676
CrossRef10
K. KAUSHANSKY. (2009) Molecular mechanisms of thrombopoietin signaling. Journal of Thrombosis and Haemostasis 7, 235-238
CrossRef11
S. N. Constantinescu. (2009) Mpl and thrombocytosis: levels matter. Blood 113:8, 1617-1618
CrossRef12
R. Tiedt, J. Coers, S. Ziegler, A. Wiestner, H. Hao-Shen, C. Bornmann, J. Schenkel, S. Karakhanova, F. J. de Sauvage, C. W. Jackson, R. C. Skoda. (2009) Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood 113:8, 1768-1777
CrossRef13
R. C. Skoda. (2009) Thrombocytosis. Hematology 2009:1, 159-167
CrossRef14
K. Kaushansky. (2009) Determinants of platelet number and regulation of thrombopoiesis. Hematology 2009:1, 147-152
CrossRef15
Claudiu V. Cotta, Raymond R. Tubbs. (2008) Mutations in Myeloid Neoplasms. Diagnostic Molecular Pathology 17:4, 191-199
CrossRef16
O Kilpivaara, R L Levine. (2008) JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia 22:10, 1813-1817
CrossRef17
R. L. Levine, D. G. Gilliland. (2008) Myeloproliferative disorders. Blood 112:6, 2190-2198
CrossRef18
R. Tiedt, H. Hao-Shen, M. A. Sobas, R. Looser, S. Dirnhofer, J. Schwaller, R. C. Skoda. (2008) Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111:8, 3931-3940
CrossRef19
(2008) CrossRef Listing of Deleted DOIs. CrossRef Listing of Deleted DOIs
CrossRef20
Junzhi Li, Yuping Xia, David J. Kuter. (2008) The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. British Journal of Haematology 111:3, 943
CrossRef21
Ayalew Tefferi. (2008) JAK and MPL mutations in myeloid malignancies. Leukemia & Lymphoma 49:3, 388-397
CrossRef22
Donna M. Williams, Ann H. Kim, Ophelia Rogers, Jerry L. Spivak, Alison R. Moliterno. (2007) Phenotypic variations and new mutations in JAK2 V617F–negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Experimental Hematology 35:11, 1641-1646
CrossRef23
Jerry L. Spivak. (2007) Phenotype and genotype in the myeloproliferative disorders. European Journal of Haematology 79:s68, 9-12
CrossRef24
Anna D. Panani. (2007) Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: Clinical implications. Cancer Letters 255:1, 12-25
CrossRef25
Brijesh Arora, Ayalew Tefferi. (2007) Advances in molecular diagnostics of myeloproliferative disorders. Expert Opinion on Medical Diagnostics 1:1, 65-80
CrossRef26
L. Teofili, M. Martini, T. Cenci, G. Petrucci, L. Torti, S. Storti, F. Guidi, G. Leone, L. M. Larocca. (2007) Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood 110:1, 354-359
CrossRef27
Campbell, Peter J., Green, Anthony R., . (2006) The Myeloproliferative Disorders. New England Journal of Medicine 355:23, 2452-2466
Full Text28
Massimo Primignani, Giovanni Barosi, Gaetano Bergamaschi, Umberto Gianelli, Federica Fabris, Raffaella Reati, Alessandra Dell'Era, Paolo Bucciarelli, Pier Mannuccio Mannucci. (2006) Role of theJAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 44:6, 1528-1534
CrossRef29
Claire N. Harrison, Anthony R. Green. (2006) Essential thrombocythaemia. Best Practice & Research Clinical Haematology 19:3, 439-453
CrossRef30
Ayalew Tefferi. (2006) The diagnosis of polycythemia vera: New tests and old dictums. Best Practice & Research Clinical Haematology 19:3, 455-469
CrossRef31
Ayalew Tefferi. (2006) A refined diagnostic algorithm for polycythemia vera that incorporates mutation screening for JAK2V617F. Current Hematologic Malignancy Reports 1:2, 81-86
CrossRef32
John M. McCarty, Pamela D. Melone, Juris P. Simanis, David Kanamori, Emmanuel N. Dessypris, G. Sakuntala Warshamana-Greene. (2006) A preliminary investigation into the action of anagrelide: Thrombopoietin–c-Mpl receptor interactions. Experimental Hematology 34:1, 87-96
CrossRef33
Isabelle Corre-Buscail, Danielle Pineau, Marjorie Boissinot, Sylvie Hermouet. (2005) Erythropoietin-independent erythroid colony formation by bone marrow progenitors exposed to interleukin-11 and interleukin-8. Experimental Hematology 33:11, 1299-1308
CrossRef34
Guido Finazzi, Claire Harrison. (2005) Essential Thrombocythemia. Seminars in Hematology 42:4, 230-238
CrossRef35
Anthony J. Bench, Heike L. Pahl. (2005) Chromosomal Abnormalities and Molecular Markers in Myeloproliferative Disorders. Seminars in Hematology 42:4, 196-205
CrossRef36
Ayalew Tefferi, Shireen Sirhan, Terra L. Lasho, Susan M. Schwager, Chin-Yang Li, David Dingli, Alexandra P. Wolanskyj, David P. Steensma, Ruben Mesa, D. G. Gilliland. (2005) Concomitant neutrophil JAK2V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. British Journal of Haematology 131:2, 166-171
CrossRef37
Ayalew Tefferi, Jerry L. Spivak. (2005) Polycythemia Vera: Scientific Advances and Current Practice. Seminars in Hematology 42:4, 206-220
CrossRef38
Giovanni Barosi, Ronald Hoffman. (2005) Idiopathic Myelofibrosis. Seminars in Hematology 42:4, 248-258
CrossRef39
Zhizhuang Joe Zhao, William Vainchenker, Sanford B. Krantz, Nicole Casadevall, Stefan N. Constantinescu. (2005) Role of Tyrosine Kinases and Phosphatases in Polycythemia Vera. Seminars in Hematology 42:4, 221-229
CrossRef40
Claire N. Harrison. (2005) Essential thrombocythaemia: challenges and evidence-based management. British Journal of Haematology 130:2, 153-165
CrossRef41
A. Tefferi, D. G. Gilliland. (2005) The JAK2V617F Tyrosine Kinase Mutation in Myeloproliferative Disorders: Status Report and Immediate Implications for Disease Classification and Diagnosis. Mayo Clinic Proceedings 80:7, 947-958
CrossRef42
Kralovics, Robert, Passamonti, Francesco, Buser, Andreas S., Teo, Soon-Siong, Tiedt, Ralph, Passweg, Jakob R., Tichelli, Andre, Cazzola, Mario, Skoda, Radek C., . (2005) A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders. New England Journal of Medicine 352:17, 1779-1790
Full Text43
Philipp S. Goerttler, Clemens Kreutz, Johannes Donauer, Daniel Faller, Thomas Maiwald, Edith Marz, Brigitta Rumberger, Titus Sparna, Annette Schmitt-Graff, Jochen Wilpert, Jens Timmer, Gerd Walz, Heike L. Pahl. (2005) Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2. British Journal of Haematology 129:1, 138-150
CrossRef44
Ross L. Levine, Martha Wadleigh, Jan Cools, Benjamin L. Ebert, Gerlinde Wernig, Brian J.P. Huntly, Titus J. Boggon, Iwona Wlodarska, Jennifer J. Clark, Sandra Moore, Jennifer Adelsperger, Sumin Koo, Jeffrey C. Lee, Stacey Gabriel, Thomas Mercher, Alan D’Andrea, Stefan Fröhling, Konstanze Döhner, Peter Marynen, Peter Vandenberghe, Ruben A. Mesa, Ayalew Tefferi, James D. Griffin, Michael J. Eck, William R. Sellers, Matthew Meyerson, Todd R. Golub, Stephanie J. Lee, D. Gary Gilliland. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:4, 387-397
CrossRef45
Oliver Bock, Gero Loch, Ulrika Schade, Reinhard von Wasielewski, Jerome Schlu
, Hans Kreipe. (2005) Aberrant expression of transforming growth factor ?-1 (TGF?-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. The Journal of Pathology 205:5, 548-557
CrossRef46
E Joanna Baxter, Linda M Scott, Peter J Campbell, Clare East, Nasios Fourouclas, Soheila Swanton, George S Vassiliou, Anthony J Bench, Elaine M Boyd, Natasha Curtin, Mike A Scott, Wendy N Erber, Anthony R Green. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. The Lancet 365:9464, 1054-1061
CrossRef47
Josef T Prchal. (2005) Polycythemia vera and other primary polycythemias. Current Opinion in Hematology 12:2, 112-116
CrossRef48
Robert Kralovics, Radek C. Skoda. (2005) Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Reviews 19:1, 1-13
CrossRef49
M.L. Randi, M.C. Putti, E. Pacquola, G. Luzzatto, L. Zanesco, F. Fabris. (2005) Normal thrombopoietin and its receptor (c-mpl) genes in children with essential thrombocythemia. Pediatric Blood & Cancer 44:1, 47-50
CrossRef50
J. Gracia Colldeforns, D. Hernández Maraver, R. de Paz Arias, F. Hernández Navarro. (2004) Síndromes mieloproliferativos crónicos. Medicine - Programa de Formación Médica Continuada Acreditado 9:21, 1332-1346
CrossRef51
Alessandro M. Vannucchi, Alberto Grossi, Alessandro Pancrazzi, Elisabetta Antonioli, Paola Guglielmelli, Francesca Balestri, Monica Biscardi, Simona Bulgarelli, Giovanni Longo, Claudio Graziano, Luigi Gugliotta, Alberto Bosi. (2004) PRV-1 , erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia. British Journal of Haematology 127:2, 214-219
CrossRef52
Cody A. Koch, Terra L. Lasho, Ayalew Tefferi. (2004) Platelet-rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV-1 assay. British Journal of Haematology 127:1, 34-39
CrossRef53
Francesco Passamonti, Daniela Pietra, Lucia Malabarba, Elisa Rumi, Matteo Giovanni Della Porta, Luca Malcovati, Maurizio Bonfichi, Cristiana Pascutto, Mario Lazzarino, Mario Cazzola. (2004) Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders. British Journal of Haematology 126:5, 650-656
CrossRef54
Heike L Pahl. (2004) Diagnostic approaches to polycythemia vera in 2004. Expert Review of Molecular Diagnostics 4:4, 495-502
CrossRef55
Jerry L Spivak. (2004) The chronic myeloproliferative disorders: Clonality and clinical heterogeneity. Seminars in Hematology 41, 1-5
CrossRef56
John M McCarty. (2004) Transplant strategies for idiopathic myelofibrosis. Seminars in Hematology 41, 23-29
CrossRef57
A.Koneti Rao. (2004) Molecular and biochemical basis for the platelet dysfunction in myeloproliferative disorders. Seminars in Hematology 41, 6-9
CrossRef58
Schafer, Andrew I., . (2004) Thrombocytosis. New England Journal of Medicine 350:12, 1211-1219
Full Text59
Claire N Harrison, Anthony R Green. (2003) Essential thrombocythemia. Hematology/Oncology Clinics of North America 17:5, 1175-1190
CrossRef60
Josef T Prchal. (2003) Classification and molecular biology of polycythemias (erythrocytoses) and thrombocytosis. Hematology/Oncology Clinics of North America 17:5, 1151-1158
CrossRef61
Erim van Os, Ya-Ping Wu, Jos G. Pouwels, Martin J. W. Ijsseldijk, Jan J. Sixma, Jan Willem N. Akkerman, Philip G. de Groot, Gijsbert van Willigen. (2003) Thrombopoietin increases platelet adhesion under flow and decreases rolling. British Journal of Haematology 121:3, 482-490
CrossRef62
Vesna Najfeld, Shai Fuchs, Paul Merando, Kimberly Lezon-Geyda, Steven Fruchtman. (2003) Fluorescence in situ hybridization analysis of the PRV-1 gene in polycythemia vera. Experimental Hematology 31:2, 118-121
CrossRef63
Ayalew Tefferi. (2003) Thrombopoietin expression and plasma concentrations in chronic myeloproliferative disorders. Leukemia Research 27:2, 121-123
CrossRef64
A. Tefferi. (2003) Polycythemia Vera: A Comprehensive Review and Clinical Recommendations. Mayo Clinic Proceedings 78:2, 174-194
CrossRef65
Jen C Wang, Ghazala Hashmi. (2003) Elevated thrombopoietin levels in patients with myelofibrosis may not be due to enhanced production of thrombopoietin by bone marrow. Leukemia Research 27:1, 13-17
CrossRef66
Jerry L. Spivak. (2003) Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry. Seminars in Hematology 40, 1-5
CrossRef67
Vesna Najfeld, Lya Montella, Angela Scalise, Steven Fruchtman. (2002) Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected*. British Journal of Haematology 119:2, 558-566
CrossRef68
Nathaniel I Berlin. (2002) Polycythemia vera: diagnosis and treatment 2002. Expert Review of Anticancer Therapy 2:3, 330-336
CrossRef69
Claire N. Harrison . (2002) Current trends in essential thrombocythaemia. British Journal of Haematology 117:4, 796-808
CrossRef70
Rosemary E. Gale. (2002) Basic sciences of the myeloproliferative diseases: Pathogenic mechanisms of ET and PV. International Journal of Hematology 76:S2, 305-310
CrossRef71
Michelle A. Elliott, Soo-Young Yoon, Pai Kao, Chin-Yang Li, Ayalew Tefferi. (2002) Simultaneous measurement of serum thrombopoietin and expression of megakaryocyte c-Mpl with clinical and laboratory correlates for myelofibrosis with myeloid metaplasia. European Journal of Haematology 68:3, 175-179
CrossRef72
Ruben A. Mesa. (2002) Clinical and scientific advances in the philadelphia-chromosome negative chronic myeloproliferative disorders. International Journal of Hematology 76:S2, 193-203
CrossRef73
R. Skoda. 2002. Thrombopoietin. .
CrossRef74
Ayalew Tefferi. (2002) Current Management of Polycythemia Vera. Leukemia & Lymphoma 43:1, 1-7
CrossRef75
Hilary A. Blacklock, Gordon A. Royle. (2001) Idiopathic erythrocytosis - a declining entity. British Journal of Haematology 115:4, 774-781
CrossRef76
A.I. Schafer. (2001) Thrombocytosis and thrombocythemia. Blood Reviews 15:4, 159-166
CrossRef77
Anthony J. R Allen, Rosemary E Gale, Claire N Harrison, Samuel J Machin, David C Linch. (2001) Lack of pathogenic mutations in the 5'-untranslated region of the thrombopoietin gene in patients with non-familial essential thrombocythaemia. European Journal of Haematology 67:4, 232-237
CrossRef78
Anthony J. Bench, Nicholas C.P. Cross, Brian J.P. Huntly, Elisabeth P. Nacheva, Anthony R. Green. (2001) Myeloproliferative disorders. Best Practice & Research Clinical Haematology 14:3, 531-551
CrossRef79
A. Tefferi, S. Murphy. (2001) Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Reviews 15:3, 121-131
CrossRef80
Ayalew Tefferi. (2001) Recent progress in the pathogenesis and management of essential thrombocythemia. Leukemia Research 25:5, 369-377
CrossRef81
Masakazu Izumi, Akihiro Takeshita, Kaori Shinjo, Kensuke Naito, Hirotaka Matsui, Kiyoshi Shibata, Kazunori Ohnishi, Takashi Kanno, Ryuzo Ohno. (2001) Decreased amount of mpl and reduced expression of glycoprotein IIb/IIIa and glycoprotein Ib on platelets from patients with refractory anemia: analysis by a non-isotopic quantitative ligand binding assay and immunofluorescence. European Journal of Haematology 66:4, 245-252
CrossRef82
B. Douglas Smith, Alison R. Moliterno. (2001) Biology and management of idiopathic myelofibrosis. Current Opinion in Oncology 13:2, 91-94
CrossRef83
Takashi Okamura, Naoko Kinukawa, Yoshiyuki Niho, Hideaki Mizoguchi. (2001) Primary Chronic Myelofibrosis: Clinical and Prognostic Evaluation in 336 Japanese Patients. International Journal of Hematology 73:2, 194-198
CrossRef84
Ayalew Tefferi. (2001) The Pathogenesis of Chronic Myeloproliferative Diseases. International Journal of Hematology 73:2, 170-176
CrossRef85
David P. Steensma, Claire N. Harrison, Ayalew Tefferi. (2001) Hydroxyurea-associated Platelet Count Oscillations in Polycythemia Vera: A Report of Four New Cases and a Review. Leukemia & Lymphoma 42:6, 1243-1253
CrossRef86
Josef T Prchal. (2001) Pathogenetic mechanisms of polycythemia vera and congenital polycythemic disorders. Seminars in Hematology 38, 10-20
CrossRef87
Junzhi Li, Yuping Xia, David J. Kuter. (2000) The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. British Journal of Haematology 111:3, 943-953
CrossRef88
Uwe Kalina, Wolf-Karsten Hofmann, Steffen Koschmieder, Sandra Wagner, Dörte Kauschat, Dieter Hoelzer, Oliver Gerhard Ottmann. (2000) Alteration of c-mpl–mediated signal transduction in CD34+ cells from patients with myelodysplastic syndromes. Experimental Hematology 28:10, 1158-1163
CrossRef89
IA Voutsadakis. (2000) Interferon-alpha and the pathogenesis of myeloproliferative disorders. Medical Oncology 17:4, 249-257
CrossRef90
, M. C. Bousse-Kerdilès, M. C. Martyré. (2000) Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. Springer Seminars in Immunopathology 21:4, 491-508
CrossRef91
Heike L. Pahl. (2000) Towards a molecular understanding of polycythemia rubra vera. European Journal of Biochemistry 267:12, 3395-3401
CrossRef92
Alessandra Battaglia, Andrea Fattorossi, Luca Pierelli, Giuseppina Bonanno, Maria Marone, Franco O. Ranelletti, Annamaria Coscarella, Rita De Santis, Simona Bach, Salvatore Mancuso, Giovanni Scambia. (2000) The fusion protein MEN 11303 (granulocyte-macrophage colony stimulating factor/erythropoietin) acts as a potent inducer of erythropoiesis. Experimental Hematology 28:5, 490-498
CrossRef93
Le Blanc, Andersson, Samuelsson. (2000) Marked heterogeneity in protein levels and functional integrity of the thrombopoietin receptor c-mpl in polycythaemia vera. British Journal of Haematology 108:1, 80-85
CrossRef94
HENK M. W. VERHEUL, DIPAK PANIGRAHY, EVELYN FLYNN, HERBERT M. PINEDO, ROBERT J. D???AMATO. (1999) Treatment of the Kasabach-Merritt Syndrome with Pegylated Recombinant Human Megakaryocyte Growth and Development Factor in Mice: Elevated Platelet Counts, Prolonged Survival, and Tumor Growth Inhibition. Pediatric Research 46:5, 562
CrossRef95
Claire N. Harrison, Rosemary E. Gale, Francesco Pezella, Anthony Mire-Sluis, Samuel J. Machin, David C. Linch. (1999) Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value. British Journal of Haematology 107:1, 139-147
CrossRef96
Soo-Young Yoon, Chin-Yang Li, Ruben A. Mesa, Ayalew Tefferi. (1999) Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology 106:3, 682-688
CrossRef97
Akira Ishiguro, Tatsutoshi Nakahata, Kousaku Matsubara, Yasuhide Hayashi, Takashi Kato, Yoko Suzuki, Toshikazu Shimbo. (1999) Age-related changes in thrombopoietin in children: reference interval for serum thrombopoietin levels. British Journal of Haematology 106:4, 884-888
CrossRef98
Martin Eilers, Harald Schulze, Karl Welte, Matthias Ballmaier. (1999) Thrombopoietin Acts Synergistically on Ca2+ Mobilization in Platelets Caused by ADP or Thrombin Receptor Agonist Peptide. Biochemical and Biophysical Research Communications 263:1, 230-238
CrossRef99
A. Cerutti, P. Custodi, . Mduranti, M. Cazzola, C. L. Balduini. (1999) Circulating thrombopoietin in reactive conditions behaves like an acute phase reactant. Clinical and Laboratory Haematology 21:4, 271-275
CrossRef100
Jaroslav F. Prchal, Josef T. Prchal. (1999) Molecular basis for polycythemia. Current Opinion in Hematology 6:2, 100
CrossRef101
Wolf-Karsten Hofmann, Uwe Kalina, Sandra Wagner, Gernot Seipelt, Christoph Ries, Dieter Hoelzer, Oliver Gerhard Ottmann. (1999) Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes. Experimental Hematology 27:3, 395-400
CrossRef102
José L. Fernández-Luna. (1999) Apoptosis and polycythemia vera. Current Opinion in Hematology 6:2, 94
CrossRef103
Mary Frances McMullin, Melanie J. Percy. (1999) Erythropoietin receptor and hematological disease. American Journal of Hematology 60:1, 55-60
CrossRef104
Rakesh K Goyal, Gregory D Longmore. (1999) Abnormalities of Cytokine Receptor Signalling Contributing to Diseases of Red Blood Cell Production. Annals of Medicine 31:3, 208-216
CrossRef105
Claire N. Harrison, Rosemary E. Gale, Adrian C. Wiestner, Radek C. Skoda, David C. Linch. (1998) The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemia. British Journal of Haematology 102:5, 1341-1343
CrossRef106
Claire N. Harrison, Rosemary E. Gale, Adrian C. Wiestner, Radek C. Skoda, David C. Linch. (1998) The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemia. British Journal of Haematology 102:5, 00-00
CrossRef107
(1998) Signal Transduction in Platelets from Patients with Polycythemia Vera. New England Journal of Medicine 339:2, 127-128
Full Text108
Schwartz, Robert S., . (1998) Polycythemia Vera — Chance, Death, and Mutability. New England Journal of Medicine 338:9, 613-615
Full Text
- Letters
